Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 10, 2009

Avexa and Progen Nix Merger Deal

  • Avexa and Progen Pharmaceuticals have agreed to terminate their merger plans. The companies realized that Progen shareholders would not approve the transaction. Consistent with the terms of the MIA, Progen will pay Avexa a break fee of A$500,000.

    Avexa made a move to take over Progen in December 2008. The combined company would focus initially on Avexa’s Phase III HIV therapy, ATC, and continue to develop selected compounds for infectious diseases and cancer.

    Then at the beginning of this year, Cytopia raised issues with the merger, claiming the combination would not have sufficient money to fund the Phase III trials in HIV. In February, Avexa reaffirmed its interest and reiterated that financing would not be an issue.

    While Avexa expected to have $60 million in cash through the merger with Progen, which would support ATC, the company says that it is still confident about its development efforts. The company anticipates initial Phase III results in the 2nd quarter of 2009.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »